Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Decisions On New Off-Label Chemotherapy Compendia Due By Early July

Executive Summary

CMS will issue decisions by early July on the possible addition of four medical compendia as approved references for coverage of off-label uses of cancer drugs and biologicals

You may also be interested in...



DrugDex Endorsed As Off-Label Chemotherapy Guide For Medicare Coverage

CMS now recognizes Thomson Micromedex's DrugDex compendium as an authoritative reference for determining off-label coverage of cancer drugs under Medicare Part B, the agency announced June 10

DrugDex Endorsed As Off-Label Chemotherapy Guide For Medicare Coverage

CMS now recognizes Thomson Micromedex's DrugDex compendium as an authoritative reference for determining off-label coverage of cancer drugs under Medicare Part B, the agency announced June 10

CMS approves off-label chemotherapy compendium

CMS will recognize the National Comprehensive Cancer Network Drugs & Biologics Compendium as an approved reference for coverage of off-label uses of cancer drugs and biologics, the agency announces June 5. Local Medicare contractors who process claims for Part B, or physician-administered, drugs would consult the compendia when deciding whether to approve claims. CMS also announces it will formally delete from its list of recognized compendia the American Medical Association Drug Evaluations compendium, which ceased publication in 1996. The decisions represent a first step in CMS' efforts to update its compendia list; decisions in the coming weeks are expected on three other references - Gold Standard's Clinical Pharmacology and Thomson Micromedex's DrugPoints and DrugDex (1"The Pink Sheet" April 14, 2008, p. 15)

Related Content

UsernamePublicRestriction

Register

PS049503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel